John Hood bags $90M for his quest to get fedratinib OK’d by FDA and catapult into the market
It took 18 months for John Hood to get the late-stage drug fedratinib back from Sanofi, assemble a small crew of execs for his startup Impact Biomedicines and bring Medicxi in for a $22.5 million round to get this JAK2 kinase inhibitor back on track. And in the last 14 days, he’s completed a deal for up to $90 million in financing needed to launch the drug — provided the FDA is willing.
“It takes a lot of money to launch a drug,” Hood tells me in an update. And now he has it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.